ArticleLa Radiologia medica2026
AI-assessed sarcopenia as an independent predictor of neoadjuvant chemotherapy outcomes in muscle-invasive bladder cancer.
Article in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeSarcopenia has already been widely investigated as a potential indicator of negative outcomes in oncology patients. Our aim was to evaluate the potential predictive role of sarcopenia assessed using an Artificial Intelligence-powered software in response to neoadjuvant chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC). MATERIALS AND
methodsIn this single-centre retrospective study, we enrolled patients diagnosed with non-metastatic MIBC who underwent NAC and had available pre-treatment mpMRI of the bladder and baseline CT scan. The follow-up MRI assessment was performed using the NacVI-RADS algorithm to evaluate response to systematic therapy. AI-based software automatically calculated the skeletal muscle index (SMI) from CT images at the L3 vertebral level. Multivariate logistic regression analysis was performed to assess independent predictors of response to NAC, and a receiver operating characteristic (ROC) analysis was subsequently conducted to provide an additional level of statistical validation.
resultsFifty-five patients were included (mean age: 67.2 years). Sarcopenia was identified in 36.4% of patients. Multivariate logistic regression revealed sarcopenia (OR: 9.08; 95% CI 1.32-61.92; p = 0.024), comorbidities (OR: 14.63; 95% CI 2.12-100.71; p = 0.006), and high NacVI-RADS scores (4-5) (OR = 2.13 95% CI 1.03-4.42; p = 0.042) as independent predictors of poor response to NAC. Receiver operating characteristic (ROC) curve analysis confirmed the high discriminative ability of SMI for predicting treatment response (AUC = 0.952).
conclusionSarcopenia, assessed by AI-powered analysis, was negatively associated with tumor response following NAC in patients with MIBC. These findings support the integration of AI-driven sarcopenia evaluation into clinical staging workflows, enabling tailored nutritional interventions and improved patient stratification. Moreover, our study reinforces the prognostic value of the NacVI-RADS scoring system in predicting NAC outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.